Skip to main content
  1. aggrego Conference Hub
  2. Breast Cancer

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

Recommended
Ibrutinib With and Following AutoHCT Well-Tolerated Among Patients With R/R Activated-B-Cell Subtype DLBCL
Glofitamab Plus Polatuzumab Vedotin Demonstrates Durable Responses Among Pretreated Patients With DLBCL, Including HGBCL
Odronextamab Monotherapy Shows Promising Antitumor Activity Among Patients With R/R DLBCL Post CAR T-Cell Therapy
R-CHOP Plus Tazemetostat Therapy Feasible Among Older Patients With Newly Diagnosed DLBCL
Impact of an Automated, Remote Monitoring, and Coaching Intervention in Reducing Hospice Cancer Family Caregiving Burden: A Multisite Randomized Controlled Trial
MicroRNAs as Biomarkers for Trastuzumab-Based Therapy in HER2-Positive Advanced Oesophago-Gastric Cancer Patients
Eating Beans Improved Gut Health in Colorectal Cancer Survivors, MD Anderson Study
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

header-info
Jun, 02, 2023
social-elements

In a cohort of 300 patients with HER2+ breast cancer, results of the TROIKA study demonstrate that random assignment of either HD201 or referent trastuzumab combined with standard chemotherapy over a duration of 12 weeks leads to no statistical efficacy differences.

 

Access the full article to read more here.

Footer branding


Footer main navigation

  • About Us
  • Contact Us
  • Privacy Policy
  • Sign in
  • Job Board

HMP Global Products

  • HMP Global Learning Network
  • Consultant360
  • VRTX

Copyright branding

© 2023 HMP Global. Aggrego is a trademark of HMP Global. All Rights Reserved.

 

<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->

Home

Site branding - mobile

Upper navigation

  • Today
    Today
  • Following
    Following
  • Specialties
    Specialties

Main navigation

  • News
    news
  • TV
    TV
  • Radio
    Radio
  • Conference Hub
    Conf hub
  • Originals
    Originals

Partners links

  • Advances
    Advances

User imageSign in

Register

Additional navigation- 1

  • Acute Basal Cell Carcinoma
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Breast Cancer
  • Early Breast Cancer
  • CAR-T Cell Therapy
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Cutaneous Squamous-Cell Carcinoma
  • Diffuse Large B-Cell Lymphoma
  • FDA Approvals
  • Febrile Neutropenia
  • Follicular Lymphoma
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Head and Neck Cancer
  • Health Care Policy
  • Hematologic Malignancies
  • Immuno Oncology
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Multiple Myeloma
  • Myelofibrosis
  • Non-Small Cell Lung Cancer
  • Oncology Nursing
  • Pediatric Oncology
  • Radiation Oncology
  • Renal Cell Carcinoma
  • Sarcoma
  • Supportive Care
  • Surgical Oncology
  • Urethral Carcinoma